AngioDynamics Expands NanoKnife System Indications Across Europe

Event summary

  • AngioDynamics has expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer.
  • The NanoKnife System uses irreversible electroporation (IRE) technology, which destroys tumor cells while preserving critical surrounding anatomy.
  • Europe accounts for approximately 28% of global IRE procedures, with annual procedures estimated to have surpassed 45,000 globally.
  • AngioDynamics will initiate the LIVER-IRE Global Registry in collaboration with the University of Manchester to evaluate outcomes in patients undergoing IRE treatment for liver tumors.

The big picture

AngioDynamics' expansion of the NanoKnife System's indications in Europe strengthens its position as a multi-organ tumor ablation platform. This move aligns with the growing demand for minimally invasive cancer treatments and the increasing incidence of cancer globally. The company's focus on differentiated tools for complex tumor ablation positions it well to capitalize on the rising number of IRE procedures, which are supported by a growing body of clinical evidence.

What we're watching

Market Penetration
How the expanded indications will affect AngioDynamics' market share in Europe, where IRE procedures are growing.
Clinical Adoption
Whether the LIVER-IRE Global Registry will accelerate physician adoption of the NanoKnife System across multiple disease states.
Technological Advancements
The pace at which advancements in image guidance and minimally invasive treatment options will drive further growth in IRE procedures.